AG Mednet and Japan's Biovisiq Bring Zero-Delay Clinical Trial Solutions to Asian Pharmaceutical Market Signed Master Services Agreement to Improve Clinical Trial Quality, Compliance and Efficiency across Burgeoning Asia Market
BOSTON, April 2, 2013 /PRNewswire/ -- Executing its mission to bring zero-delay imaging technology to clinical trials around the world, AG Mednet today announced the signing of a Master Services Agreement with Biovisiq, a Japanese imaging core laboratory (ICL). As the adoption of Asia and Japan-specific clinical trials continues to grow, AG Mednet and Biovisiq are partnering to set the new industry standard for imaging data quality, compliance and efficiency.
According to industry research, more than half of all image-related clinical trial query stoppages result from preventable human errors that can delay a trial for up to seven weeks. The AG Mednet Submission Quality and Compliance module immediately detects errors that result in query stoppages and gives ICLs a system to verify information, automatically update support systems including EDC (electronic data capture), and dramatically reduce the amount of queries returned for correction or re-scanning.
In clinical trials conducted using AG Mednet technology, sponsors experience a more than 75% query reduction rate, resulting in significant cost savings and faster decision times.
"Biovisiq is dedicated to providing reliable, cost-effective and compliant imaging services to Japan and the growing Asian pharmaceutical market. We are confident that our partnership with
AG Mednet will help accomplish this goal," said Shigeto Ogawa, president and CEO, Biovisiq.
"Asia is the next frontier in clinical trial research as recruitment in the United States and Western Europe is getting harder to achieve," said Abraham Gutman, president and CEO of AG Mednet. "As clinical trials move closer to the patient base across Asia, we look forward to working with the talented team at Biovisiq to make a significant contribution to the Asia and Japan-specific drug discovery and development markets."
For more information about AG Mednet and how the new AG Mednet module delivers benefits and quality assurance to imaging trial sponsors, imaging core labs, clinical research organizations and principal investigators in a way not possible until today, please visit www.agmednet.com/zerodelay.
About AG Mednet
AG Mednet automates, expedites and improves outcomes in clinical trials by ensuring quality and compliance within critical medical imaging processes. Founded in 2005, AG Mednet is the leading quality compliance partner for image data submission and collection for pharmaceutical, biotechnology and medical device companies, imaging core labs and clinical research organizations managing clinical trials globally. More than 16,000 registered users across thousands of investigator sites in 60 countries use AG Mednet to participate in projects sponsored by each of the world's top 20 pharmaceutical, biotech and medical device companies.
Biovisiq, Japan's leading core lab, has provided a wide range of medical imaging-related solution services since 2005. Well-experienced radiological technologists of BVJ offer timely and high-quality consulting and analysis, helping pharmaceutical and medical device developing companies run their clinical trials smoothly with medical doctors in their various fields. Adding to its strong local clientele in Japan, Biovisiq seeks overseas business opportunities in other Asian countries.
Dawn Sullivan or Molly Delaney
SOURCE AG Mednet